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Aims No drug has been proven efficacious to prevent the post-pericardiotomy syndrome (PPS), but colchicine seems safe
and effective for the treatment and prevention of pericarditis. The aim of the COlchicine for the Prevention of the
Post-pericardiotomy Syndrome (COPPS) trial is to test the efficacy and safety of colchicine for the primary preven-
tion of the PPS.
Methods
and results
The COPPS study is a multicentre, double-blind, randomized trial. On the third post-operative day, 360 patients
(mean age 65.7+12.3 years, 66% males), 180 in each treatment arm, were randomized to receive placebo or col-
chicine (1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in
patients ≥70 kg, and halved doses for patients ,70 kg or intolerant to the highest dose). The primary efficacy end-
point was the incidence of PPS at 12 months. Secondary endpoint was the combined rate of disease-related hospi-
talization, cardiac tamponade, constrictive pericarditis, and relapses. Baseline characteristics were well balanced
between the study groups. Colchicine significantly reduced the incidence of the PPS at 12 months compared with
placebo (respectively, 8.9 vs. 21.1%; P ¼ 0.002; number needed to treat ¼ 8). Colchicine also reduced the secondary
endpoint (respectively, 0.6 vs. 5.0%; P ¼ 0.024). The rate of side effects (mainly related to gastrointestinal intolerance)
was similar in the colchicine and placebo groups (respectively, 8.9 vs. 5.0%; P ¼ 0.212).
Conclusion Colchicine is safe and efficacious in the prevention of the PPS and its related complications and may halve the risk of
developing the syndrome following cardiac surgery.
ClinicalTrials.gov number, NCT00128427.
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Introduction
The post-pericardiotomy syndrome (PPS) is a relatively common
and troublesome complication following cardiac surgery and
occurring a few days to several weeks after the surgical operation
in 10–40% of patients.1–4 Treatment is empirical and based on
aspirin or non-steroidal anti-inflammatory drugs (NSAIDs). Corti-
costeroids are considered in the case of contraindications or
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failure of NSAIDs. At present, no preventive pharmacological strat-
egies (either NSAIDs or corticosteroids) have been proven to be
efficacious in the prevention of the syndrome.5,6
Anecdotal reports have suggested that colchicine may be useful
for the treatment of patients with the PPS.7 On the basis of the
efficacy of colchicine as an anti-inflammatory drug in acute gouty
attacks,8,9 familial Mediterranean fever,10,11 and its efficacy in the
treatment and secondary prevention of recurrent pericarditis,12–
24 colchicine has also been proposed for the primary prevention
of the PPS in a preliminary report from Israel, where a statistically
non-significant trend towards a reduction in the incidence of the
syndrome was recorded in patients treated with colchicine.4
The PPS may have a troublesome course and complicate the
post-operative period with even life-threatening events such as
cardiac tamponade; moreover, it may prolong the hospital stay
and increase management costs. Preventive measures may be valu-
able to reduce post-operative morbidity, improve the quality of life
of patients, and reduce management costs.
The COlchicine for the Prevention of the Post-pericardiotomy
Syndrome (COPPS) trial is a prospective, randomized, double-
blind, placebo-controlled, multicentre trial aimed at evaluating
the efficacy and safety of colchicine for the primary prevention
of the PPS following cardiac surgery. This is the first multicentre,




Prospective, randomized, double-blind, placebo-controlled, multicen-
tre trial.
Participants and setting
The study population consisted of 360 patients enrolled at six hospitals
in Italy (Maria Vittoria Hospital, Torino; Ospedali Riuniti, Bergamo;
Mauriziano Hospital, Torino; Niguarda Hospital, Milano; San Maurizio
Regional Hospital, Bolzano; and Ospedale degli Infermi, Rivoli).
Inclusion criteria
All consecutive patients undergoing cardiac surgery were recruited. Eli-
gible patients had no contraindication to colchicine, were able to
provide informed consent, and had no unfavourable short-term
outlook. Inclusion criteria were: candidate for cardiac surgery, age ≥
18 years, and informed consent. All patients have to be willing and
able to give informed consent and to comply with the study pro-
cedures and follow-up.
Exclusion criteria
Patients meeting any of the following exclusion criteria were not eli-
gible for the study: known severe liver disease or current transamin-
ases .1.5 times the upper normal limit, current serum creatinine
above 2.5 mg/dL, known myopathy or elevated baseline pre-operative
creatine kinase, known blood dyscrasias or gastrointestinal disease,
pregnant and lactating women or women of childbearing potential
not protected by a contraception method, known hypersensitivity to
colchicine, or current treatment with colchicine for any indications.
Interventions
Patients were randomized to receive placebo or colchicine on top of
standard therapy. Treatment with placebo or colchicine started on
the third post-operative day. Colchicine was given at the dosage of
1.0 mg twice daily for the first day followed by a maintenance dose
of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved
doses for patients ,70 kg or intolerant to the highest dose.
Endpoints
The primary study endpoint was the incidence of the PPS at 12
months. The secondary endpoint was the combined rate of
disease-related hospitalization, cardiac tamponade, constrictive peri-
carditis, and recurrent pericarditis.
Criteria for the diagnosis of the PPS4 are reported in Table 1. The
diagnosis of PPS was based on the presence of at least two criteria.
Endpoint data were assessed by clinical records and regular clinical
visits.
Randomization
Participants were randomly assigned to treatments by a central
computer-based, automated sequence. Randomization was based on
permuted blocks, with a block size of four. The random allocation
sequence was implemented by sequentially numbered containers. All
participants and trial investigators were blinded to randomized treat-
ment. Tablets identical in colour, shape, and taste were provided in
blister packs. Unblinded datawere made available exclusively to an inde-
pendent data and safety and monitoring board in the case of severe side
effects. Data were collected using case report forms and clinical events
adjudication forms. Data were managed blinded to treatment assign-
ments. A blinded clinical endpoint committee adjudicated all events.
Safety
During follow-up, a monitoring and recording of all adverse events was
performed. A severe adverse event was considered an untoward event
which was fatal or life-threatening or required hospitalization or was
significantly or permanently disabling or medically significant (may jeo-
pardize the patient and may require medical or surgical intervention to
prevent an adverse outcome). A safety monitoring committee did one
interim analysis, masked to treatment assignment.
Statistical analysis and sample size
A total of 360 patients, 180 in each treatment arm, were needed to
detect a difference in the PPS rate of 22.0 and 11.0% between the
two treatment arms (placebo and colchicine) with a power of 80%
using a two-sided P ¼ 0.05 level test. The estimated rate of the PPS
of 22.0% in the placebo group and 11.0% in the colchicine group
Table 1 Criteria for the diagnosis of the
post-pericardiotomy syndrome
1. Fever lasting beyond the first post-operative week without evidence
of systemic or focal infection
2. Pleuritic chest pain
3. Friction rub
4. Evidence of pleural effusion
5. Evidence of new or worsening pericardial effusion
The diagnosis of post-pericardiotomy syndrome was based on the presence of at
least two criteria.
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was based on the preliminary study from Israel.4 Analyses were per-
formed by intention to treat.
Data were expressed as mean+ standard deviation. Comparisons
between patient arms were performed using the Mann–Whitney test
for continuous variables and a x2 analysis for categorical variables. A
P-value of ,0.05 was considered to show statistical significance.
Time-to-event distributions were estimated using the Kaplan–Meier
method and compared using the log-rank test. Analyseswere performed
with the software package SPSS 13.0 (Chicago, IL, USA). The number of
patients needed to treat (NNT) was estimated with its confidence inter-
val (CI) using the GraphPad SoftwareQuickCalcs (San Diego, CA, USA).
Results
Baseline characteristics
Baseline patient characteristics were similar between the two study
groups and are reported in Table 2. A detailed flow diagram of the
study is reported in Figure 1.
Main outcomes
Colchicine significantly reduced the incidence of the PPS at 12
months compared with placebo (respectively, 8.9 vs. 21.1%; P ¼
0.002; NNT 8, relative risk reduction—RRR 57.9%, 95% CI
27.3–75.6) and the secondary endpoint including disease-related
hospitalization, cardiac tamponade, constrictive pericarditis, and
relapses at 18 months (respectively, 0.6 vs. 5.0%; P ¼ 0.024;
NNT 22, RRR 88.9%, 95% CI 13.2–98.6) (Table 3 and Figure 2).
Most PPS events occurred in the first 30 days (85% of all PPS
events; Figure 3).
Safety and side effects
The rates of side effects and drug withdrawal were similar in the
colchicine and placebo groups (respectively, 8.9 vs. 5.0%; P ¼
0.212 for side effects and 11.7 vs. 6.7%; P ¼ 0.145 for drug withdra-
wal), although colchicine showed a trend towards an increased
rate of both events. No severe side effects were recorded.
Gastrointestinal intolerance was the only side effect recorded
during the study, while one case of myotoxicity was recorded in
the placebo group and related to concomitant use of a statin.
Colchicine was discontinued in 21 cases (11.7%). Patient or
medical decision was the cause of drug withdrawal in 2.8% of
cases for the colchicine group and 1.7% for the placebo group.
A detailed list of side effects and drug withdrawal data is reported
in Table 4.
Discussion
The COPPS trial was designed to assess the efficacy and safety of
colchicine for the primary prevention of the PPS. This possible
indication was tested for the first time in a preliminary prospective,
open-label, randomized trial of colchicine (1.5 mg/day) compared
with placebo beginning on the third post-operative day in 163
patients who underwent cardiac surgery.4 Fifty-two of the 163
(31.9%) initial patients were excluded because of post-operative
complications, non-compliance, or gastrointestinal side effects. At
3 months, PPS was diagnosed in 19 of 111 patients (17.1%) who
completed the study: 5 of 47 (10.6%) in the colchicine group
and 14 of 64 (21.9%) in the placebo group. The difference
showed a possible trend towards statistical significance (P,
0.135); however, these results can be considered only as prelimi-
nary, because of the limited sample size, the lack of an
intention-to-treat analysis, and the short observation time.
The PPS is a common complication after cardiac surgery and can
be often prolonged and disabling. Colchicine might represent a
cheap, safe option not only for the treatment of the syndrome,
but also for its primary prevention.
Colchicine is efficacious and safe in the treatment and preven-
tion of pericarditis12–23 and has been proposed as a first treatment
option for recurrent pericarditis (class I indication) and optional for
acute pericarditis (class IIa indication) in the 2004 European guide-
lines on the management of pericardial diseases.25 At present, no
pharmacological options have been shown efficacious in the pre-
vention of the PPS.5,6
In the COPPS study, colchicine was safe and efficacious in the
prevention of the PPS and its related complications. Colchicine
halved the incidence of the PPS and its related complications
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Age (mean+ SD) 67+11 65+14
Female sex (%) 65 (36.1) 56 (31.1)
Medical history (%)
Hypertension 125 (69.4) 121 (67.2)
Diabetes mellitus 45 (25.0) 39 (21.7)
Tobacco use 54 (15.0) 41 (11.4)
Previous MI 37 (20.6) 37 (20.6)
Previous cardiac surgery 11 (6.1) 10 (5.6)
Previous pericarditis 2 (1.1) 2 (1.1)
Pre-operative pericardial effusion 2 (1.1) 3 (1.6)
Pre-operative data (%)
Creatinine clearance ,60 mL/min 22 (12.2) 33 (18.3)
Ejection fraction 54+10 54+12
NYHA class I– II 118 (65.6) 127 (70.5)
NYHA class III– IV 62 (34.4) 53 (29.5)
Surgery indication (%)
Angina 66 (36.7) 66 (36.7)
Myocardial infarction 18 (10.0) 31 (17.2)
Mitral valve disease 37 (20.6) 36 (20.0)
Aortic valve disease 44 (24.4) 35 (19.4)
Aorta disease 5 (2.8) 5 (2.8)
Other 10 (5.5) 7 (3.9)
Cardiac surgery type (%)
CABG 77 (42.8) 92 (51.1)
Valvular surgery 55 (30.6) 51 (28.3)
Aorta surgery 8 (4.4) 4 (2.2)
Combined surgery 37 (20.6) 30 (16.7)
Other 3 (1.6) 3 (1.6)
CABG, coronary artery bypass grafting; MI, myocardial infarction.
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providing evidence for the first time that pharmacological preven-
tion of the PSS is possible and safe.
Most of the PPS events (85% of all PPS) occurred in the first
month, and thus a preventive treatment with colchicine for the
first 4 weeks following surgery seems appropriate.
No severe side effects were documented, and gastrointestinal
side effects were equally distributed between the colchicine and
placebo groups, although colchicine showed a trend towards an
increased rate of such complications. Diarrhoea is relatively
common, affecting up to 10% of patients on colchicine treatment
for pericarditis. The use of weight-adjusted doses without a
loading dose and especially lower doses (i.e. 0.5 mg/day to
0.5 mg b.i.d.) may be a way to reduce this side effect, improving
drug compliance.24,26,27
The exact mechanism of colchicine action is not fully understood.
Most of the pharmacological effects of colchicine on cells involved in
inflammation appear to be related to its capacity to disrupt microtu-
bules.28 Colchicine inhibits the process of microtubule self-assembly
by binding b-tubulin with the formation of tubulin–colchicine com-
plexes. This action takes place either in the mitotic spindle or in the
interphase stage, thus colchicine inhibits the movement of intercel-
lular granules and the secretion of various substances.7,8,12,18 By this
mechanism, colchicine is able to inhibit various leucocytes functions,
and this effect should be the most significant for the anti-
inflammatory action. Moreover, colchicine shows a preferential con-
centration in leucocytes and its peak concentration may be more
than 16 times the peak concentration in plasma. This seems to be
related to its therapeutic effect.28
The major study limitation is related to the definition of the PPS
because there is no general agreement on how to diagnose the
syndrome. The diagnosis of PPS is challenging as there is no
single finding that is pathognomonic for the condition. At
present, the definition of the PPS is rather arbitrary. There are
neither specific guidelines nor consensus documents. The only
published criteria for the diagnosis have been proposed in the pre-
liminary study from Israel,4 which is the premise of the present
multicentre, double-blind, randomized trial. We adopted the
same diagnostic criteria for the PPS. They can be criticized and
considered weak because they could lead to the diagnosis of PPS
also for cases with mild pleuro-pericardial involvement following
surgery, which may be considered trivial post-operative sequelae.
Nevertheless, they represent the first attempt to have an objective
approach to the diagnosis. Otherwise, the diagnosis would be
based on a rather subjective ‘clinical judgement’, thus probably
including only more severe cases. In the clinical arena, the PPS is
not a single disease but rather a syndrome with different
Figure 1 Study flow diagram.
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expressions of pleural and/or pericardial involvement with a wide
spectrum of clinical severity ranging from mild isolated asympto-
matic effusions to cardiac tamponade and/or massive pleural effu-
sions. On this basis, if all cases are considered, the incidence of the
PPS may seem relatively high compared with what is encountered
as ‘significant disease’ in most severe cases from daily practice.
However, many cases of the PPS may not be diagnosed in the clini-
cal setting, and delayed recognition and treatment may be respon-
sible for complications and recurrences, often the cause of
readmissions.
Nevertheless, in the COPPS study, colchicine showed to reduce
all the major components of the PPS as reported in the adopted
diagnostic criteria (pleuritic chest pain, friction rub, and pleural
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PPS at 12 months 38 (21.1) 16 (8.9) 0.002
Fever beyond first
post-operative weeka
7 (3.9) 6 (3.3) 0.982
Pleuritic chest pain 23 (12.8) 7 (3.9) 0.004
Friction rub 15 (8.3) 5 (2.7) 0.036
Pleural effusion 46 (25.6) 22 (12.2) 0.002
New or worsening
pericardial effusionb
41 (22.8) 23 (12.8) 0.019
Secondary endpointc (%) 9 (5.0) 1 (0.6) 0.024
Recurrence 2 (1.1) 0 (0.0) 0.485
Cardiac tamponade 1 (0.6) 0 (0.0) 0.992
Constrictive pericarditis 0 (0.0) 0 (0.0) 0.982
PPS-related
hospitalization
6 (3.3) 1 (0.6) 0.130
Mean follow-up (months) 18.5 20.2 0.252
PPS, post-pericardiotomy syndrome.
aWithout evidence of systemic or focal infection.
bPre-existing pre-operative pericardial effusions worsened in one case (0.6%) in
the placebo group and two cases (1.2%) in the colchicine group (P ¼ 0.964).
cIncluding combined rate of recurrence, cardiac tamponade, constrictive
pericarditis, post-pericardiotomy syndrome-related hospitalization.
Figure 3 Kaplan–Meier event-free survival curves according to
the treatment groups in the first 30 days (85% of all post-
pericardiotomy syndrome events). Curves remained parallel
after the first month.
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Side effects (%) 9 (5.0) 16 (8.9) 0.212
Severe side effects 0 (0.0) 0 (0.0) 0.212
Other side effects 9 (5.0) 16 (8.9) 0.133
Gastrointestinal 8 (4.4) 16 (8.9) 0.939
Alopecia 0 (0.0) 0 (0.0)
Anorexia 0 (0.0) 0 (0.0)
Hepatoxicity 0 (0.0) 0 (0.0)
Myotoxicity 1 (0.6) 0 (0.0)
Bone marrow toxicity 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0)
Drug withdrawal (%)
Overall 12 (6.7) 21 (11.7) 0.145
Related to side effects 9 (5.0) 16 (8.9) 0.212
Patient or medical
decision
3 (1.7) 5 (2.8) 0.728
Figure 2 Proportion of patients developing the primary end-
point (post-pericardiotomy syndrome at 12 months; relative
risk reduction 57.9%, 95% confidence interval 27.3–75.6;
P ¼ 0.002) and the secondary endpoint (recurrence, cardiac tam-
ponade, constrictive pericarditis, and post-pericardiotomy
syndrome-related hospitalization; relative risk reduction 88.9%,
95% confidence interval 13.2–98.6; P ¼ 0.024).
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and pericardial effusions), and thus showing a ‘real’ preventive
effect even on several components of the pleuro-pericardial invol-
vement following cardiac surgery.
In conclusion, colchicine is safe and efficacious in the primary pre-
vention of the PPS and its related complications and may halve the
risk of developing the syndrome following cardiac surgery. Such a
finding is particularly important for clinical practice because the
post-operative management may be complex, troublesome and
empirical anti-inflammatory therapy may not be efficacious.29,30
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